Objective: To examine the association between smoking and the 15-year cumulative incidence of age-related macular degeneration (AMD).
Methods: Population-based longitudinal cohort study of people in Beaver Dam, Wisconsin, who were aged 43 to 84 years (N = 4926) in 1987-1988. Participants were examined in 1988-1990 and were reexamined at 5-year intervals during a 15-year period. Age-related macular degeneration status was determined by grading stereoscopic color fundus photographs.
Results: Controlling for age, sex, and baseline AMD severity, people who were current smokers at baseline, compared with those who never smoked, were at increased risk of incident early AMD (odds ratio, 1.47; 95% confidence interval, 1.08-1.99; P = .01) and for progression of AMD (odds ratio, 1.43; 95% confidence interval, 1.05-1.94; P = .02) during a 15-year follow-up. There were few associations of specific characteristics of smoking (eg, intensity, pack-years smoked, duration, and age at initiation and quitting) with AMD outcomes.
Conclusions: Smoking appears to be related to the long-term incidence and progression of AMD. This has important health care implications because early AMD increases the risk of developing late AMD and smoking behavior is modifiable.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1001/archopht.126.1.115 | DOI Listing |
Mol Ther
January 2025
Department of Molecular Medicine, University of Southern Denmark; Odense, 5230, Denmark. Electronic address:
Neovascular age-related macular degeneration and diabetic macular edema are leading causes of vision-loss evoked by retinal neovascularization and vascular leakage. The glycoprotein microfibrillar-associated protein 4 (MFAP4) is an integrin αβ ligand present in the extracellular matrix. Single-cell transcriptomics reveal MFAP4 expression in cell-types in close proximity to vascular endothelial cells including choroidal vascular mural cells and retinal astrocytes and Müller cells.
View Article and Find Full Text PDFEye (Lond)
January 2025
Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Purpose: To utilize optical coherence tomography (OCT) and SS-OCT angiography (SS-OCTA) for quantifying morphological changes seen in eyes with recalcitrant neovascular age-related macular degeneration (nAMD) transitioned to intravitreal faricimab injections during the manufacturer's recommended induction phase of treatment.
Methods: Fifty-four treatment-recalcitrant patients (60 eyes) were recruited. OCT and SS-OCTA images were obtained at 0 and 3 months.
Eye (Lond)
January 2025
Maidstone Hospital Eye Department, Hermitage Lane, Maidstone, UK.
Background And Objectives: Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2, has shown promise in treating neovascular age-related macular degeneration (nAMD). This study evaluates 1-year outcomes of faricimab in treatment-experienced nAMD patients.
Methods: This single-centre retrospective cohort study included patients previously treated for nAMD who switched to faricimab between November 2022 and March 2024.
Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have risen exponentially in usage and have been shown to exert neuroprotective and anti-inflammatory effects across multiple organ systems. This study investigates whether GLP-1RAs influence the risk for age-related ocular diseases.
Design: Retrospective cohort study.
Pharmaceutics
January 2025
Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET and Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba 5000, Argentina.
Background/objectives: Neurodegenerative ocular diseases, such as age-related macular degeneration (AMD) and glaucoma, represent growing public health concerns. Oxidative stress plays a key role in their development, damaging retinal cells and accelerating disease progression. Melatonin (Mel) is a potent antioxidant with neuroprotective properties; however, it faces limitations such as low solubility.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!